Based on TCGA analysis and clinical validation, our study showed that HOXC6 was excessively expressed in patients with CRC, and elevated expression of HOXC6 was linked to the progression of malignancy and unfavorable survival outcomes in patients with CRC. The gene discussed is HOXC6; the disease is colorectal carcinoma.